Stay updated with breaking news from Vial Access Needle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior...
(RTTNews) - Heron Therapeutics, Inc. (HRTX) announced on Wednesday that it has submitted a Prior Approval Supplement or PAS Submission to the FDA ...
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration...
On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.
Zynrelef's expanded FDA approval for soft tissue and orthopedic surgeries, offering superior pain management with lower pain scores and opioid consumption.